Noteworthy SEC Filing: Eleven Biotherapeutics, Inc Has Another Bullish Trade, Flagship Ventures Fund 2007 Bought Stake!

Noteworthy SEC Filing: Eleven Biotherapeutics, Inc Has Another Bullish Trade, Flagship Ventures Fund 2007 Bought Stake!

The New Flagship Ventures Fund 2007 Holding in Eleven Biotherapeutics, Inc

Flagship Ventures Fund 2007 filed with the SEC SC 13D/A form for Eleven Biotherapeutics, Inc. The form can be accessed here: 000119312516772374. As reported in Flagship Ventures Fund 2007’s form, the filler as of late owns 6.9% or 1,679,007 shares of the Health Care–company.

Eleven Biotherapeutics, Inc stake is a new one for the and it was filed because of activity on November 15, 2016. We feel this shows Flagship Ventures Fund 2007’s positive view for the stock.

Eleven Biotherapeutics, Inc Institutional Sentiment

Latest Security and Exchange filings show 28 investors own Eleven Biotherapeutics, Inc. The institutional ownership in Q3 2015 is low, at 76.73% of the outstanding shares. This is increased by 4426014 the total institutional shares. 18599775 were the shares owned by these institutional investors. In total 6 funds opened new Eleven Biotherapeutics, Inc stakes, 8 increased stakes. There were 16 that closed positions and 6 reduced them.

2 managers had the stock in their top Ten. Notable investors are: Flagship Ventures 2007 General Partner Llc..

Rotella Capital Management Inc is an institutional investor bullish on Eleven Biotherapeutics, Inc, owning 190947 shares as of Q3 2015 for 0.15% of its portfolio. Jeremy Green Redmile Group Llc owns 848351 shares or 0.04% of its portfolio. MA Third Rock Ventures Llc have 1.09% of their stock portfolio for 4841591 shares. Further, Sarissa Capital Management Lp reported stake worth 0.02% of its US stock portfolio. The MA Flagship Ventures 2007 General Partner Llc owns 1907008 shares. Eleven Biotherapeutics, Inc is 2.89% of the manager’s US portfolio.

Business Profile

Eleven Biotherapeutics, Inc. is a preclinical-stage biopharmaceutical company. The Company applies its AMP-Rx platform to the discovery and development of protein therapeutics to treat diseases of the eye. The Company’s product candidate, which is still in preclinical development, is EBI-031, which was designed, engineered and generated using its AMP-Rx platform and are developing as an intravitreal injection for diabetic macular edema (DME) and uveitis. The Company’s therapeutic approach is based on the role of cytokines in diseases of the eye, its understanding of the structural biology of cytokines and its ability to design and engineer proteins to modulate the effects of cytokines. The Company is developing EBI-031 as an intravitreal injection for DME and uveitis. In addition to EBI-031, the Company has another product candidate in early preclinical development, which is designed to block vascular endothelial growth factor (VEGF).

SEC Form 13D is filed within 10 days, by anyone who acquires beneficial ownership of 5%+ of any public firm. Activist investors and practices such as: company breakups, hostile takeovers, and change of control events, are permitted for this form filers. A filer must promptly update its 13D filing in case of acquisition or disposition of 1% or more of the securities that are the subject of the filing.

Insitutional Activity: The institutional sentiment increased to 2.29 in Q2 2016. Its up 1.29, from 1 in 2016Q1. The ratio improved, as 5 funds sold all Eleven Biotherapeutics Inc shares owned while 4 reduced positions. 5 funds bought stakes while 4 increased positions. They now own 2.51 million shares or 36.45% more from 1.84 million shares in 2016Q1.

Blackrock Fund Advsrs reported 1,624 shares or 0% of all its holdings. Fiduciary Tru holds 10,000 shares or 0% of its portfolio. Bankshares Of Montreal Can accumulated 15,000 shares or 0% of the stock. Moreover, Reilly Financial Advsrs Ltd has 0% invested in Eleven Biotherapeutics Inc (NASDAQ:EBIO) for 100 shares. Flagship Ventures 2007 General Partner Limited Liability Corporation has 2.98% invested in the company for 1.91M shares. Gru One Trading Ltd Partnership, a Illinois-based fund reported 600 shares. Geode Management Lc has invested 0% of its portfolio in Eleven Biotherapeutics Inc (NASDAQ:EBIO). Guggenheim Cap Ltd Limited Liability Company owns 10,331 shares or 0% of their US portfolio. Blackrock Institutional Trust Na last reported 0% of its portfolio in the stock. Savings Bank Of Mellon Corporation has 67,483 shares for 0% of their US portfolio. Citigroup holds 600 shares or 0% of its portfolio. Bank Of America De last reported 0% of its portfolio in the stock. Moreover, Renaissance Technologies Ltd has 0% invested in Eleven Biotherapeutics Inc (NASDAQ:EBIO) for 118,500 shares. Susquehanna Gru Limited Liability Partnership has 26,654 shares for 0% of their US portfolio. Goldman Sachs Group Inc holds 0% or 13,343 shares in its portfolio.

About 1.16 million shares traded hands. Eleven Biotherapeutics Inc (NASDAQ:EBIO) has risen 376.92% since April 18, 2016 and is uptrending. It has outperformed by 372.49% the S&P500.

Eleven Biotherapeutics, Inc. is a preclinical-stage biopharmaceutical company. The company has a market cap of $60.11 million. The Firm applies its AMP-Rx platform to the discovery and development of protein therapeutics to treat diseases of the eye. It currently has negative earnings. The Company’s product candidate, which is still in preclinical development, is EBI-031, which was designed, engineered and generated using its AMP-Rx platform and are developing as an intravitreal injection for diabetic macular edema and uveitis.

Eleven Biotherapeutics Inc (NASDAQ:EBIO) Ratings Coverage

Out of 2 analysts covering Eleven Biotherapeutics (NASDAQ:EBIO), 0 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 0 are positive. $8.35 is the highest target while $0.40 is the lowest. The $4.38 average target is 74.50% above today’s ($2.51) stock price. Eleven Biotherapeutics has been the topic of 4 analyst reports since August 15, 2015 according to StockzIntelligence Inc. The company was downgraded on Tuesday, January 19 by Leerink Swann. The company was maintained on Wednesday, March 16 by Citigroup. The rating was maintained by Leerink Swann with “Outperform” on Saturday, August 15. Citigroup downgraded Eleven Biotherapeutics Inc (NASDAQ:EBIO) on Tuesday, January 19 to “Neutral” rating.

According to Zacks Investment Research, “Eleven Biotherapeutics, Inc. is engaged in the discovery and development of protein therapeutics to treat eye diseases primarily in the United States. The company develops its therapeutics through AMP-Rx, a proprietary protein engineering platform. Its principal preclinical product candidate consist of EBI-005, a novel IL-1 receptor antagonist for the topical treatment of dry eye disease and allergic conjunctivitis, EBI-029, a novel inhibitor of the cytokine IL-6 for the treatment of certain retinal diseases, such as DME and EBI-028, a novel inhibitor of the cytokine IL-17 for the treatment of uveitis. Eleven Biotherapeutics, Inc. is based in Cambridge, United States.”

EBIO Company Profile

Eleven Biotherapeutics, Inc., incorporated on February 25, 2008, is a preclinical-stage biopharmaceutical company. The Firm applies its AMP-Rx platform to the discovery and development of protein therapeutics to treat diseases of the eye. The Company’s product candidate, which is still in preclinical development, is EBI-031, which was designed, engineered and generated using its AMP-Rx platform and are developing as an intravitreal injection for diabetic macular edema (DME) and uveitis.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Leave a Comment